Lilly Shares Rise After Retatrutide Yields 19% Weight Loss

Eli Lilly presented late-stage trial results at the American Diabetes Association Scientific Sessions in New Orleans showing a 4 mg dose of retatrutide produced about 19% average weight loss in treatment‑naive type 2 diabetes patients and people living with obesity. Shares of Lilly rose roughly 4% following the data release.

The company released full results from two late‑stage studies. Lilly reported that the 4 mg dose produced weight reductions similar to the highest dose of its marketed tirzepatide product, Zepbound. Tolerability at 4 mg was described as favorable, with treatment discontinuation rates and instances of vomiting remaining relatively low; higher retatrutide doses were linked to more side effects.

Lilly also reported additional outcomes from the trials, including meaningful improvements in knee osteoarthritis pain and measures of sleep apnea alongside the weight loss findings.

At the same meeting, Lilly presented data for its oral obesity candidate Foundayo, previously known as orforglipron. Analyses from the Phase 3 ATTAIN‑1 and ATTAIN‑2 trials showed the pill was associated with significant weight loss in women across different stages of menopause. Lilly highlighted Phase 2 results for eloralintide, reporting signals of strong efficacy and tolerability in that study.

Novo Nordisk said U.S. prescriptions for its oral Wegovy exceeded 3 million since the product’s January launch. Despite that milestone, Novo Nordisk’s U.S.-listed shares declined during the session while Lilly’s stock outperformed peers.

Market research and analyst commentary accompanied the data release. Citi analysts wrote that the 4 mg retatrutide results are “compelling enough that first‑line positioning cannot be dismissed,” and suggested the treatment could be “the next step for patients who have exhausted Lilly’s tirzepatide efficacy.” Goldman Sachs analyst Asad Haider described the Wegovy pill launch as “one of the best launches we’ve seen in pharmaceuticals — and it didn’t come at the expense of injectables,” and added that Lilly retains longer‑term advantages and the ability to scale internationally.

J.P. Morgan analyst Chris Schott wrote that Lilly “has the pieces in place to further raise the standard of care in the obesity space,” and projected the company could extend its leadership in the more than $200 billion incretin and obesity market. Citi Research’s Geoff Meacham wrote that Lilly’s incretin portfolio is not built around a single product, noting that orforglipron and retatrutide “carry development programs with enough indication breadth to make them category‑defining franchises.” RBC Capital Markets’ Trung Huynh wrote that the depth of Lilly’s pipeline “highlighted its leadership growing rather than a narrowing gap with competitors.”

The presentations added to a series of clinical and commercial updates from both companies at the ADA meeting, as investors and analysts assessed near‑term sales progress and later‑stage clinical results across oral and injectable obesity therapies.